期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Vein transplantation using human umbilical cord blood stem cells in the treatment of stroke sequela 被引量:7
1
作者 yong man1, jianbin li2, bo yang3, ji ma1 1department of cerebral surgery, the second people’s hospital of zhengzhou, zhengzhou 450000, henan province, china 2Red Cross Blood Center of henan province, zhengzhou 450000, henan province, china 3department of Neurosurgery, the First Affiliated hospital of zhengzhou University, zhengzhou 450000, henan province, china 《Neural Regeneration Research》 SCIE CAS CSCD 2006年第7期618-621,共4页
BACKGROUND: Transplanted mononuclear cell(MNC)of umbilical blood can survive in central nervous system (CNS)of host through blood brain barrier,differentiate into nerver cells,migrate to damaged site and integrate mor... BACKGROUND: Transplanted mononuclear cell(MNC)of umbilical blood can survive in central nervous system (CNS)of host through blood brain barrier,differentiate into nerver cells,migrate to damaged site and integrate morphological strucgh and function with nerve cells of host so as to improve deficiencies of sensatory function,motor function and cognitive function and influence on stroke sequela.OBJECTIVE: To observe the vein transplantation of human umbilical cord blood stem cells(HUCBSC) for improving neurological function,limb funtion and activity of daily living of patients with stroke and evaluate the reliability.DESIGN: Self-controlled study.SETTING: Department of Neurosurgery,the Second People's Hospital of Zhengzhou City;Red-crossed Blood Center of Henan Province;Department of Neurosurgery,the Fist Affiliated Hospital of Zhenzhou University.PARTICIPANTS:A total of 10 patients with stoke sequela were selected from Department of Cerebral Surgery,the Second People's Hospital of Zhengzhou City from April to December 2005.There were 9males and 1 female aged from 35to 75years with the mean age of 56 years.All of them were diagnosed with CT and MRI examination and coincidence with diagnostic criteria of stroke established by the Fourth National Academic Meeting for Cerebrovascular Disease.All patients provided informed consent. METHODS:80-140 mL umbilical blood of term birth of newborn was selected hermetically and maintained in sterile plastic bag.And then,the blood was centrifugated at the speed of 1500 r/min for 30 minutes at 22℃ in order to separate MNC,i.e.,HUCBSC.In addition,after final diagnosis during hospitalization,stroke patients were perfused with HUCBSC through superficial vein of back of the hand.Each patient was averagely penfused with 6 portions of HUCBSC(cellular numbers≥1×108/portion)and the interval between each portion was 1-7 days with the mean interval of 4 days.MAIN OUTCOME MEASURES: ①Neurological function of stroke patients was evaluated with neurological function deficiency(NFD)before treatment and at 3 months after treatment.The scale includes consciousness,level fix function.facial paralysis,language,muscle force of upper limbs,muscle force of lower limb and step function.The total scores ranged from 0 to 45; meanwhile,the lower the scores were,the better the neurological function of limbs was. ②Motor function of injured limbs was evaluated with Fugl-Meyer Assessment (FMA),including motor function of upper limbs.motor function of lower limbs,balance ability,sensory function and motion of joint.The total scores ranged from 0 to 226;meanwhile,the higher the scores were,the better the motor function of limbs was.③Activities of daily living(ADL)was evaluated with Barthel Index(BI),including having meals,taking a bath,dressing oneself,putting on clothes,walking in balance and stair activity.The total scores ranged from 0 to 100;meanwhile,the higher the scores were,the stronger the ADL was.RESULTS:A total of 10 patients were involved in the final analysis.After treatment,NFD of stroke patients was (10.9±5.09)points,which was lower than that before treatment[(25.4±6.09)points,t=8.213,P<0.01].In addition,after treatment,FMA and BI of stroke patients were(80.9±25.00)points and(81.1±15.93)points,re spectively,which were higher than those before treatment[(31.9+21.85)points,(36.2+19.41)points,t=13.024,13.670,P<0.01]. Immuno-suppressive drugs were not used during the whole therapeutic procedure;moreover,immunological rejection and allergic reaction were not observed during the same period.CONCLUSION:Transplanting HUCBSC through superficial vein of back of the hand is regarded as a simple and safe method for the treatment of stroke sequela. 展开更多
关键词 CELL STEM Vein transplantation using human umbilical cord blood stem cells in the treatment of stroke sequela
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部